Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

IMPORTANCE: The anti–programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Abida, Wassim, Cheng, Michael L., Armenia, Joshua, Middha, Sumit, Autio, Karen A., Vargas, Hebert Alberto, Rathkopf, Dana, Morris, Michael J., Danila, Daniel C., Slovin, Susan F., Carbone, Emily, Barnett, Ethan S., Hullings, Melanie, Hechtman, Jaclyn F., Zehir, Ahmet, Shia, Jinru, Jonsson, Philip, Stadler, Zsofia K., Srinivasan, Preethi, Laudone, Vincent P., Reuter, Victor, Wolchok, Jedd D., Socci, Nicholas D., Taylor, Barry S., Berger, Michael F., Kantoff, Philip W., Sawyers, Charles L., Schultz, Nikolaus, Solit, David B., Gopalan, Anuradha, Scher, Howard I.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459218/
https://ncbi.nlm.nih.gov/pubmed/30589920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5801
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados